Maia Biotech says Phase 3 THIO-104 trial in third-line NSCLC enrolls 65 patients
Bitget2026/09/22 12:47- Maia Biotechnology reported progress in its pivotal Phase 3 THIO-104 trial of ateganosine as third-line therapy for advanced NSCLC.
- Enrollment reached 65 randomized patients, supporting the company’s plan to exceed 100 by year-end.
- Results were already presented as an interim assessment from the Phase 2 THIO-101 study.
- The update indicated disease control in heavily pretreated patients, outperforming typical third-line chemotherapy outcomes.
- FDA Fast Track status for NSCLC could speed review timelines, supporting a potential earlier regulatory pathway if Phase 3 data hold.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The British Pound rallies on a UK growth upgrade and gives more than half back
Only twice in history! S&P 500 equal-weight index is expected to record seven consecutive weeks of decline this week
The S&P 500 Equal Weight Index is expected to fall for a seventh consecutive week. If this downward trend continues through Friday, it will mark only the third time in history that the index has experienced seven straight weeks of decline.
Trump “bites” Powell, demanding his resignation from the Federal Reserve Board, citing severe cost overruns in headquarters renovation.
U.S. President Trump on Wednesday called for former Federal Reserve Chairman Powell to resign from his position as a Fed governor, following an inspector general report on the Federal Reserve headquarters renovation project, which highlighted a series of management issues that led to significant cost overruns.
Crypto prices
More
